The purpose of this study is to evaluate the efficacy of the combination of Methenamine + Methylthioninium chloride compared to phenazopyridine (comparator product) in the symptomatic relief of dysuria.
* Single blind, randomized, prospective study. * Length of experience: 03 days to 07 days. * 03 visits (days 1, 4 and 7). * Evaluation of the efficacy and safety of the medication. * Shall be assessed for adverse events.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
316
• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
Centro de Medicina Reprodutiva Carlos Isaia Filho Ltda
Porto Alegre, Rio Grande do Sul, Brazil
Marcio Antonio Pereira Clinica de Endocrinologia
São José dos Campos, São Paulo, Brazil
AFIP
São Paulo, Brazil
Savmed Clinica Médica S/C Ltda.
São Paulo, Brazil
Efficacy of treatment in the symptomatic relief of dysuria
Time frame: 3 days
Safety of the study medication
To assess the safety of the study medication on the occurrence, type, intensity and frequency of adverse reactions during the treatment period.
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.